Pheochromocytomas Completed Phase 2 Trials for Everolimus (DB01590)

Also known as: Pheochromocytoma / Chromaffin cell neoplasm (morphologic abnormality) / Phaeochromocytoma / Pheochromocytoma (morphologic abnormality) / Phaeochromocytoma [Ambiguous]

IndicationStatusPhase
DBCOND0071316 (Pheochromocytomas)Completed2
clinicaltrials.gov IdentifierTitlePurposeDrugs
NCT01152827RAD001 in Pheochromocytoma or Nonfunctioning CarcinoidTreatment